PhorMed's lead technology, RP-323, is a

gene repair therapy

What we do

Discovering new approaches to therapy in the field of genomic medicine.

About Us

We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted gene repair, immunotherapy, and stem cell activator for treating neurological diseases, cancers and blood disorders.

Read More


We are happy to announce that you can now be part of this exciting technology and help make a difference by investing in PhorMed through Equity Crowdfunding.




RP-323 treats diseases upstream where issues start. It has the ability to add a needed phosphate to a pathway turning the switch on or off inside the DNA (differentiation), clearing the pathway allowing transcription of DNA and expresses a protein producing a change such as cell division (proliferation) or cause cell death(apoptosis).


Watch Video


After multiple clinical studies RP-323 has been found to be safe and the company is now prepared to enter into the next phase of clinical trials advancing its pipeline in collaboration with two clinical sites in Atlanta Georgia.

Read More


PhorMed Inc is committed to good corporate citizenship. Our policy is to conduct our business affairs honestly and ethically.


PhorMed acquires COVID-19 patent rights

On March 24, 2020, PhorMed acquired the Anti-Virus and COVID-19 treatment patent rights from Prof. Richard L. Chang. PhorMed plans to research and develop a treatment for COVID-19 using its platform technology, RP-323.
Read More


Stuart Greene joins PhorMed as the new Marketing & Business Development Director

On January 1, 2020, welcomes Mr. Stuart Greene to PhorMed. He brings fresh ideas and new vision while also bringing many years of professional experience to our team.  Mr. Greene will be the department head with the title of Marketing and Business Development Director. 
Read More


Equity Crowd Funding on StartEngine goes live

On December 5, 2019, PhorMed’s Equity Crowd Funding campaign went live. Click here to see campaign.
Read More